Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

OGK-2 reported for 6 months of 2023 by RAS

7/28/23 OGKB

Astrakhan Power Supply Company reported for 6 months of 2023 by RAS

7/28/23 ASSB

Positive Technologies and Morocco discuss the creation of a cybersecurity JV

7/28/23 POSI

RusHydro opened the first electric carsharing in Sakhalin

7/28/23 HYDR

Positive Technologies reported for 6 months of 2023 by RAS

7/28/23 POSI

Sistema is interested in acquiring Ladoga House-Building Plant

7/28/23 SGZH

Procter & Gamble reported for 6 months of 2023

7/28/23 PG

Colgate reported for 6 months of 2023

7/28/23 CL

Sistema is interested in acquiring Ladoga House-Building Plant

7/28/23 AFKS

Rusal discussed with Nigeria the restoration of aluminum production in the country

7/28/23 RUAL